Neumora Therapeutics Inc. Common Stock

NMRA | NASDAQ

$0.69

-$0.04 (-5.48%)

At close: Sep 21, 2026, 4:00 PM ET

$0.71

+$0.02 (+3.42%)

Pre-market: Sep 22, 2026, 9:01 AM ET

Fiscal Year Period Ending	FY 2025 Dec 30, 2025	FY 2024 Dec 30, 2024	FY 2023 Dec 30, 2023	FY 2022 Dec 30, 2022	FY 2021 Dec 30, 2021	FY 2020 Dec 30, 2020
Net Income	-236.93M	-243.79M	-235.93M	-130.9M	-237.31M	-99.27M
Depreciation & Amortization	208K	631K	668K	594K	538K	105K
Stock-Based Compensation	29.88M	39.99M	17.24M	8.3M	4.27M	1.68M
Other Working Capital	-508K	19.76M	-8.32M	-5.7M	-202K	1.55M
Other Non-Cash Items	841K	-1.78M	63.64M	14.06M	158.09M	70.77M
Deferred Income Tax	n/a	n/a	n/a	n/a	-53K	3.08M
Change in Working Capital	-437K	22.64M	-8.9M	-6.95M	-961K	-3.12M
Operating Cash Flow	-206.44M	-182.94M	-163.28M	-114.9M	-75.42M	-26.76M
Capital Expenditures	n/a	n/a	-117K	-511K	-817K	-1.3M
Cash Acquisitions	n/a	-775K	n/a	n/a	n/a	n/a
Purchase of Investments	-85.8M	-312.22M	-109.07M	-226.37M	n/a	n/a
Sales Maturities Of Investments	251.17M	242.44M	178.17M	71.87M	n/a	n/a
Other Investing Acitivies	3.15M	n/a	-4.59M	-13M	n/a	-9.94M
Investing Cash Flow	168.52M	-70.56M	64.39M	-168.01M	-817K	-11.24M
Debt Repayment	57.16M	n/a	n/a	n/a	n/a	55.91M
Common Stock Repurchased	n/a	n/a	-491K	n/a	n/a	-2K
Dividend Paid	n/a	n/a	n/a	n/a	n/a	n/a
Other Financial Acitivies	n/a	7.91M	-948K	3.53M	1.37M	n/a
Financial Cash Flow	77.09M	21.6M	231.94M	115.74M	293.51M	230.1M
Net Cash Flow	39.17M	-231.89M	133.05M	-167.17M	217.27M	192.1M
Free Cash Flow	-206.44M	-182.94M	-163.4M	-115.41M	-76.24M	-28.06M
Adj. Free Cash Flow	-236.32M	-222.93M	-180.64M	-123.71M	-80.51M	-29.74M
Maintenance CapEx	n/a	n/a	-117K	-511K	-538K	-105K
Growth CapEx	n/a	n/a	n/a	n/a	-279K	-1.2M
Owner Earnings	-206.44M	-182.94M	-163.4M	-115.41M	-75.96M	-26.87M